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There is evidence that CCK-8 may interact with opioids and that both systems are probably implicated in pain modula- 
tion. In order to elucidate this relationship we sought to examine factors governing the movement of CCK-8 from the 
spinal cord into the extracellular space. We report that CCK-8 like immunoreactivity, as measured by RIA, is released 
from the spinal cord of the rat in vivo, following potassium stimulation and by direct activation of high threshold peri- 
pheral afferents by stimulation of the sciatic nerve. Also, we show that CCK-8 release is inhibited by the p-selective opioid 
receptor agonist DAGOL. Naloxone totally reversed the effect produced by DAGOL, implying an opiate mediated 
mechanism. 
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1. INTRODUCTION 
Cholecystokinin octapeptide (CCK(26-33); 
CCK-8) is the most abundant peptide in the human 
central nervous system (CNS) and this octapeptide 
is present throughout the CNS of a number of 
mammalian species [l-3]. The physiological ac- 
tions attributed to CCK are as diverse as its 
distribution. The physiological action of CCK-8 in 
the gastrointestinal tract is excitatory. It is a potent 
activator of digestion, pancreatic secretion, and 
gall-bladder contraction, as well as increasing gut 
motility. In the CNS, the physiological actions at- 
tributed to CCK include regulation of satiation [4], 
modulation of catecholaminergic activity [5] and 
regulation of hypothalamic peptides [6]. A variety 
of effects have been observed after central ad- 
ministration of CCK-8. These include hypothermia 
[7], hyperglycemia [8], and sometimes analgesia 
[9]. Also, electrophysiological data have shown 
both excitatory and inhibitory actions of CCK in 
the CNS [lO,ll]. 
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At the present time there is supporting evidence 
that CCK-8 may interact with opioid systems. It is 
known that CCK-8 physiologically increases 
respiration [12], whereas a well-known side effect 
of morphine is respiratory depression and, pro- 
bably the most important point is the fact that 
many of the CCK-containing loci are areas ob- 
served to contain high concentrations of en- 
dogenous opioids, with many of these areas 
implicated in pain modulation. 
Besides, the distribution of enkephalins and 
CCK are strikingly similar. Hence, a functional 
relationship may exist between them, though 
sulfated CCK-8 does not bind to opiate receptors 
in the brain [13]. At present, however, the results 
concerning the CCK-8/opiate relationship are con- 
troversial [9]. Utilizing a spinal superfusion pro- 
cedure, we sought to examine factors governing 
the movement of CCK-8 from the spinal cord into 
the extracellular space. Hence, we report here that 
CCK-8-like immunoreactivity, as measured by 
RIA, is released from the spinal cord of the rat in 
vivo, following potassium stimulation (50 mm), 
and by direct activation of high threshold 
peripheral afferent by stimulation of the sciatic 
nerve. Also, we show that this effect is inhibited by 
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the /c-selective opiate agonist [D-AlaZMePhe4,Gly- 
o15]enkephalin (DAGOL). Naloxone totally rever- 
sed the effect produced by DAGOL, implying an 
opiate mediated mechanism. 
2. MATERIALS AND METHODS 
2.1. Animals 
Experiments were performed in male Wistar rats weighing 
500-700 g under urethane (1.25 mg/kg) anaesthesia. The 
animals were artificially ventilated through a tracheal cannula. 
The heart rate and blood pressure were continuously 
monitored, and the central temperature was kept constant by 
means of an homeothermic blanket system. 
2.2. Spinal perfusion procedures 
To perfuse the spinal space an exposure of the cisterna magna 
was made by a midline incision and blunt dissection, followed 
by incision of the dura and arachnoid membranes. A piece of 
10 cm of polythene tubing (0.28 mm Ld., 0.61 mm o.d., 
PORTEX) was advanced down the subarachnoid space to the 
lumbar area. The tip of this tubing served as an inflow cannula 
and ACSF was pumped in at a rate of 110 rl/min with a Gilson 
peristaltic pump. The ACSF was withdrawn with another 
polyethylene tube positioned at the opening of the cisterna 
magna at a rate of 100 cl/min using a second peristaltic pump. 
Before entering the animal’s body, the perfusion fluid was 
warmed (37 + 5°C) and was continuously oxygenated (95% 0, 
5% CO& Normal ACSF medium consisted of (in mM): 134 
NaCl, 5 KCl, 1.25 KHzP04, 2 MgSO+ 2 CaClz, 16 NaHCOs, 
10 glucose. Experiments were conducted by first flushing the 
subarachnoid space with ACSF for 1 h to allow stabilization of 
the preparation, and then collecting 5 min (500~1) fractions. 
Statistical significance of the results was assessed by Student’s 
I-test (P 5 0.05). 
2.3. Radioimmunoassay 
Perfusate samples were collected in plastic tubes and shell 
frozen on dry-ice. Samples were lyophilized and stored at 
- 20°C until assayed. For assay, samples were reconstituted to 
l/3 of their original volume with assay buffer prior to their 
determination. The radioimmunoassay procedure for CCK 
employed in the present experiments is the same as that 
previously published by other authors 114,151. We have used 
synthetic CCK rabbit antiserum (no.3440) as our CCK antibody 
source. This antiserum recognized the carboxyl-terminal of 
CCK and gastrin equally, so radiolabeled gastrin is used as a 
tracer in our RIA procedure and all data, unless otherwise in- 
dicated, are expressed in femtomoles of gastrinr, equivalent. 
The sensitivity of the assay is 0.2 fmol/tube with 6% intraassay 
and 10% in interassay variation. Reconstituted lyophilized 
samples were chromatographed on 1 x 100 cm columns of 
Sephadex G-50 superfine at 4°C and 0.1 ml/min flow rate. Col- 
umns were equilibrated and samples eluted with 0.01 M 
potassium phosphate buffer, pH 7.6. Blue dextran 2000 (Phar- 
macia) and rzsI (New England Nuclear) were used to 
characterize the void volume and salt peaks, respectively. Frac- 
tions of 1 ml were collected, and assayed for CCK using the 
radioimmunoassay procedure described above. 
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2.4. Stimulation procedures 
The concentration of KC1 in the ACSF was raised to produce 
a final concentration of 50 mM K’ while a corresponding 
amount of NaCl was removed from the ACSF solution to 
minimize undesirable osmotic effects. 
To stimulate somatosensory input into the lumbar spinal cord 
of the rat, the sciatic nerve was exposed and prepared for 
stimulation and recording of the compound action potential. 
Stimulation of the nerve was performed with rectangular pulses 
3-4 V, 0.05 ms, 50 Hz for activation of Acr and A,8 fibers and 
40-50 V, 0.05 ms, 50 Hz for recruitment of A6 and C fibers. 
3. RESULTS AND DISCUSSION 
CCK-8-like immunoreactivity was observed to 
be present in the resting superfusate of the spinal 
cord of the anaesthetised rat. The mean resting 
levels in these samples were above the absolute sen- 
sitivity of the RIA used (0.55 + 0.12 fmol/ml per 
5 min) (n = 20), which is in accordance with other 
authors [ 161. The addition of potassium (50 mM in 
excess) to the infused artificial CSF resulted in a 
160% increase in CCK-8 above baseline in the 
spinal superfusate (n = 5, fig.1). The increase was 
significant (P 5 0.05, Student’s t-test). Upon 
substitution of normal CSF, CCK-8 levels fell 
within limits of baseline variability. The localiza- 
tion of CCK-8 in synaptosomal fractions [ 17,181 
and the in vitro experiments demonstrating an in- 
crease following depolarization suggest that 
CCK-8 may exist within releasable pools. 
To examine whether CCK-8 is released from the 
spinal cord following activation of specific af- 
ferent fiber populations, we stimulated the rat 
sciatic nerve bilaterally, which resulted in a 282% 
increase in CCK-8 release (after A&/C fiber 
stimulation). This provides direct evidence that 
CCK-8 is released from rat spinal cord in vivo by 
activating nociceptive primary afferents. 
We have also examined whether the spinal ap- 
plication of the p-selective opiate agonist, 
DAGOL, at concentrations known to produce 
analgesia (1 nM) can affect CCK-8 release from rat 
spinal cord in vivo. Following superfusion with 
1 nM DAGOL, the resting release of CCK-8 was 
substantially decreased (fig.2). Furthermore, 
bilateral stimulation of the sciatic nerve at inten- 
sities that clearly caused the release of CCK-8 
before the addition of DAGOL now failed to in- 
crease the release of CCK-8 (fig.2). Following sub- 
cutaneous injection of naloxone hydrochloride 
(0.1 mg/kg), stimulation of the sciatic nerve at the 
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Fig.1. Release of CCK-8 from superfused rat spinal cord in 
response to high potassium concentrations (50 mM) (open 
bars). The figure shows the amount (in fmol/ml per 5 min 
fractions) of CCK-8 released in the perfusing medium. The 
baseline, as observed 15 min prior to the administration of 
50 mM K+ is shown to indicate the basal evels of CCK-8 release 
in the perfusate. The results shown are the mean f SE from 5 
animals. The K+-induced effect was statistically significant as 
assessed by Student’s t-test (P c: 0.05). 
same intensity in the continued presence of in- 
trathecal DAGOL fully restored the evoked release 
of CCK-8, suggesting that the effect observed is 
opiate mediated and selective for the p-receptor 
type. 
The addition of capsaicin (3 x 10e4 M) to the 
superfusion medium failed to have any significant 
A4 M/C AC/C A4 *r/c AC/C CAP 
Fig.2. Release of CCK-8 from superfused rat spinal cord in 
response to sciatic nerve stimulation and stimulation with 
capsaicin (CAP). Each value is the mean f SE from five 
experiments. Statistical significance was assessed by Student’s t- 
test (P 5 0.05). To examine whether CCK-8 is released from the 
spinal cord following activation of specific afferent fiber 
populations, we stimulated the rat sciatic nerve bilaterally, 
while superfusing segments of the spinal cord were receiving 
sensory input from the sciatic nerve. During stimulation the 
compound action potential was monitored to determine the 
stimulus intensity required to activate A& fibers alone, and 
that required to recruit M/C-fibers. 
effect on CCK-8 levels. The actions of capsaicin in 
the spinal cord seem to be restricted to nociceptive 
primary sensory neurons [19]. In our experiments 
direct superfusion of capsaicin into the spinal cord 
failed to increase the release of CCK-8 from basal 
levels. On the other hand, chemical stimulation 
with potassium (50 nM) or electrical stimulation of 
the sciatic nerve produced a significant release of 
CCK-8. This suggests that we are measuring intrin- 
sic CCK-8 rather than CCK-8 from primary af- 
ferents. It is possible that the external stimuli that 
we have used activate interneurons, from which 
CCK-8 is released through an interaction with the 
p-opioid receptor. 
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